Overview / Abstract: |
Significant advances in treatment with novel agents for B-cell non-Hodgkin’s lymphoma (NHL) have improved patient outcomes and survival. However, many patients are at high-risk of relapse, meriting a precision approach to reduce the rate of recurrence and improve outcomes. The identification of molecular subtypes, the persistence of clinical challenges, and the anticipated emergence of clinical data necessitate a collaborative treatment approach to ensure individualized care for patients with diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. Educational Objectives - At the conclusion of this session, participants should be able to demonstrate the ability to: - Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care - Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with lymphoma - Discuss current recommendations for diagnostic testing for lymphoma to facilitate treatment selection - Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of lymphoma with attention to cost/benefit and toxicity considerations - Evaluate resources to increase patient access and engagement |
Expiration |
Jan 30, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
AACME - 1.00 AMA PRA Category 1 Credit; ACPE - 1.00 hours (0.1 CEUs); ANCC - 1.2 contact hours; APRN - 0.5 contact hours pharmacology credit |
Accreditation |
Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology |
Presenters / Authors / Faculty |
Paul A. Hamlin, MD |
Activity Specialities / Related Topics |
Pharmacology, Oncology / Cancer / Radiation Therapy, Nutrition / Dietary, Hematology, Genetics |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com. |
Keywords / Search Terms |
Rockpointe, PCME, Non-Hodgkin’s lymphoma, NHL, B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, oncology, hematology, molecular subtypes, Free CE CME |